Work

The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy

Year: 2017

Type: article

Source: Cancer Immunology Immunotherapy

DOI: 10.1007/s00262-017-2091-y

Authors: David Briere, Niranjan Sudhakar, David M. Woods, Jill Hallin, Lars D. Engstrom, Ruth Aranda, Harrah Chiang, Andressa L. Sodré, Peter Olson, Jeffrey S. Weber, James G. Christensen

Institutions: Mirati Therapeutics (United States), NYU Langone Health

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: Mirati Therapeutics

OpenAlex ID: W2767373327

FWCI: 5.546

Cites: 68

Cited by: 145

Related to: 10